Personalis Inc
NASDAQ:PSNL
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.15
6.34
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Personalis Inc
Personalis Inc
Cash Equivalents
Personalis Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Personalis Inc
NASDAQ:PSNL
|
Cash Equivalents
$75.8m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash Equivalents
$4.6B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
30%
|
CAGR 10-Years
24%
|
|
|
Danaher Corp
NYSE:DHR
|
Cash Equivalents
$2.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-4%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Cash Equivalents
$71.6m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-6%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Cash Equivalents
$1.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-3%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash Equivalents
$1.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
13%
|
CAGR 10-Years
9%
|
|
Personalis Inc
Glance View
Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company is headquartered in Menlo Park, California and currently employs 325 full-time employees. The company went IPO on 2019-06-20. The firm is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The company provides sequencing and data analysis services to support the development of cancer therapies. Its NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. The company also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.
See Also
What is Personalis Inc's Cash Equivalents?
Cash Equivalents
75.8m
USD
Based on the financial report for Sep 30, 2024, Personalis Inc's Cash Equivalents amounts to 75.8m USD.
What is Personalis Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-3%
Over the last year, the Cash Equivalents growth was 5%. The average annual Cash Equivalents growth rates for Personalis Inc have been -2% over the past three years , -3% over the past five years .
You don't have any saved screeners yet
